Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03240393 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Carcinoma
Non-Small-Cell Lung Cancer

Interventions

DRUG: INC280

Sponsor

Novartis Pharmaceuticals